Drug Profile
Research programme: PSMA ATAC therapeutics - Heidelberg Pharma Research
Alternative Names: Anti-PSMA antibody-targeted amanitin conjugate - Heidelberg Pharma Research; Anti-PSMA ATAC; PSMA antibody drug conjugates - Heidelberg Pharma Research; PSMA-ATACLatest Information Update: 20 Nov 2023
Price :
$50
*
At a glance
- Originator Heidelberg Pharma
- Developer Heidelberg Pharma Research
- Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action RNA polymerase II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 15 Nov 2023 Heidelberg Pharma Research has patent protection for site-specific ATAC conjugates in Europe
- 28 Apr 2022 No recent reports of development identified for preclinical development in Prostate-cancer in Germany (IV)
- 10 Apr 2021 Adverse events and pharmacodynamics data from a preclinical studies in Prostate cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)